Defunct Company
Total Trials
36
As Lead Sponsor
34
As Collaborator
2
Total Enrollment
2,883
NCT00073398
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
Phase: Phase 1/2
Role: Lead Sponsor
Start: Nov 30, 2003
Completion: Mar 31, 2013
NCT00090480
Vaccine Treatment for Advanced Breast Cancer
Start: Aug 31, 2004
Completion: Sep 30, 2007
NCT00105053
Vaccine Treatment for Hormone Refractory Prostate Cancer
Start: Mar 31, 2005
NCT00255827
Vaccine Treatment for Surgically Resected Pancreatic Cancer
Start: Nov 30, 2005
NCT00300612
Vaccine Treatment for Advanced Malignant Melanoma
Start: Mar 31, 2006
NCT00333502
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Start: May 31, 2006
Completion: Apr 30, 2012
NCT00420732
Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer
Phase: Phase 2
Start: Jan 31, 2007
Completion: Dec 31, 2014
NCT00569387
Vaccine Study for Surgically Resected Pancreatic Cancer
Start: Dec 31, 2007
NCT00614601
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
Start: Jan 31, 2008
NCT00746746
A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Role: Collaborator
Start: Jun 30, 2008
Completion: Jun 30, 2011
NCT00739609
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
Phase: Phase 1
Start: Aug 31, 2008
Completion: Oct 31, 2012
NCT00753740
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
Start: Sep 30, 2008
Completion: May 31, 2010
NCT01072981
Immunotherapy Study for Surgically Resected Pancreatic Cancer
Phase: Phase 3
Start: Apr 30, 2010
Completion: May 31, 2016
NCT01380769
A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
Start: Jun 30, 2011
Completion: Oct 31, 2014
NCT01774578
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Phase: Phase 2/3
Start: Feb 28, 2013
Completion: Jun 18, 2016
NCT01792050
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Completion: Jul 7, 2017
NCT01836432
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Start: May 31, 2013
Completion: Mar 24, 2017
NCT02052648
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Start: Mar 31, 2014
Completion: Jun 20, 2019
NCT02054520
Immunotherapy Study for Patients With Stage IV Melanoma
Start: Jun 30, 2014
Completion: Jan 5, 2021
NCT02073123
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Start: Jul 31, 2014
Completion: Jul 3, 2019
NCT02187302
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Completion: Jan 31, 2017
NCT02077881
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Start: Aug 31, 2014
Completion: Oct 17, 2018
NCT02374385
Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine
Start: Nov 30, 2014
Completion: Jun 30, 2015
NCT02380677
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Start: Apr 30, 2015
Completion: Oct 4, 2017
NCT02405585
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Completion: Jul 30, 2016
NCT02035358
Immunotherapy Study for Metastatic Renal Cell Cancer
Start: May 31, 2015
Completion: Jan 12, 2021
NCT02389985
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Start: Jul 31, 2015
Completion: Oct 18, 2018
NCT02502708
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Start: Oct 31, 2015
Completion: Feb 28, 2020
NCT02648711
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Completion: May 7, 2018
NCT02460367
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Start: Jan 31, 2016
Completion: Jan 13, 2021
NCT02835729
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Start: Jul 31, 2016
Completion: Dec 27, 2019
NCT03164603
NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
Start: Jun 29, 2017
Completion: Sep 25, 2019
NCT03165188
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Phase: N/A
Start: Sep 1, 2017
Completion: Dec 8, 2020
NCT03372239
Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers
Start: Nov 21, 2017
Completion: Apr 16, 2018
NCT03301636
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
Start: Dec 8, 2017
Completion: Nov 4, 2019
NCT03852446
Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers
Phase: Early Phase 1
Start: Mar 5, 2018
Completion: Aug 14, 2018